Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results.
H Lundbeck A/S presented Phase Ib data for Lu AF28996 in advanced Parkinson's disease, showing it increases good on-time, reduces off-time and dyskinesia severity. A Phase II trial for the drug is now underway.
H. Lundbeck A/S has begun the Phase II DARE2 placebo-controlled trial for its oral dopamine agonist prodrug Lu AF28996 in advanced Parkinson's disease, following positive Phase Ib results. The drug showed tolerable side effects and signs of improved motor control.